RT Book, Section
A1 Poewe, Werner
A1 Mahlknecht, Philipp
A2 Watts, Ray L.
A2 Standaert, David G.
A2 Obeso, Jose A.
SR Print(0)
ID 55794234
T1 Chapter 15. Pharmacological Treatment of Parkinson's Disease
T2 Movement Disorders, 3e
YR 2012
FD 2012
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-161312-5
LK neurology.mhmedical.com/content.aspx?aid=55794234
RD 2024/04/20
AB The  first  empirical  attempts  of  a  pharmacological  treatment  of  Parkinson's  disease  (PD)  were  made  in  the  1860s  by  Ordenstein  and  Charcot  in  Paris  by  using  extracts  from  Hyscyamus  niger,Atropia  belladonna,  and  Datura  stramonium  containing  the  anticholinergic  compounds  hyoscine  and  scopolamine.1,2  With  the  development  of  synthetic  anticholinergic  drugs  in  the  1940s3  these  agents  became  the  mainstay  of  antiparkinsonian  drug  treatment.  However,  while  improving  tremor  and  rigidity,  they  had  little  effect  on  akinesia.4